TITLE

Valeant Prescribes Itself $700M in HY

AUTHOR(S)
Sheahan, Matthew
PUB. DATE
November 2010
SOURCE
High Yield Report;11/22/2010, Vol. 21 Issue 47, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the plans of Canadian specialty pharmaceutical company Valeant Pharmaceuticals International to issue 700 million U.S. dollar in junk bonds to repay term loan debt.
ACCESSION #
55539388

 

Related Articles

  • Issuers Price Nearly $7B in HY. Sheahan, Matthew // High Yield Report;9/24/2012, p31 

    The article reports on the success of ten companies to sell 6.725 billion dollars worth of new issues on the junk bond market on September 23, 2012. Valeant Pharmaceutical International was able to sell 2.25 billion dollars in a two-part deal. Ford Motor successfully sold 1 billion dollars in...

  • Valeant Prices $1.2B HY Deal. Sheahan, Matthew // High Yield Report;9/27/2010, Vol. 21 Issue 39, p9 

    The article reports on a junk bond sold by Valeant Pharmaceuticals on September 21, 2010.

  • Valeant Offering $2.25B in HY. Sheahan, Matthew // High Yield Report;9/24/2012, p14 

    The article reports on a three-part junk bond offering worth 2.25 billion dollars of Valeant Pharmaceutical International.

  • Valeant Selling $1.5B in HY Drive-By. Sheahan, Matthew // High Yield Report;3/7/2011, Vol. 22 Issue 10, p4 

    The article Valeant Pharmaceuticals' issuance of junk bonds worth 1.5 billion U.S. dollars to pay down debt.

  • Valeant Prices $1.5B in Two-Part Junk Deal. Sheahan, Matthew // High Yield Report;3/7/2011, Vol. 22 Issue 10, p15 

    The article reports on junk bonds worth 1.5 billion U.S. dollars issued by Valeant Pharmaceuticals International.

  • Valeant Sells $2.25B in Two-Part Deal. Sheahan, Matthew // High Yield Report;9/24/2012, p29 

    The article reports on the success of Valeant Pharmaceutical International to sell bonds worth 2.25 billion dollars in a two-part junk bond offering that will help fund its acquisitions.

  • Valeant Prices $1B in Upsized Bond Deal. Sheahan, Matthew // High Yield Report;11/22/2010, Vol. 21 Issue 47, p20 

    The article focuses on the one billion U.S. dollars in junk bonds issued by Valeant Pharmaceuticals International in a deal upsized from 700 million U.S. dollars on November 25, 2010.

  • Valeant Plans $850M Bond Sale. Sheahan, Matthew // High Yield Report;11/18/2013, p23 

    The article reports on the move by Valeant Pharmaceuticals as of mid-November 2013 to sell 850 million dollars in senior unsecured notes due 2021 to be used to redeem its debt, with Goldman Sachs, Bank of America Merrill Lynch and JPMorgan serving as bookrunners.

  • Valeant Deal Has Pledge of $12B in HY. Sheahan, Matthew // High Yield Report;6/30/2014, p1 

    The article reports on the high yield bonds pledged by banks financing the acquisition by Valeant Pharmaceuticals International of health care firm Allergan in 2014. Topics covered include the value of leveraged loans received to back the deal, the launch by Valeant of a stock exchange offer for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics